Get the Stockscreener App
2.76
0.36%
-0.01
After Hours:
2.78
0.02
+0.72%
Xortx Therapeutics Inc stock is traded at $2.76, with a volume of 10,536.
It is down -0.36% in the last 24 hours and up +18.97% over the past month.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
See More
Previous Close:
$2.77
Open:
$2.76
24h Volume:
10,536
Relative Volume:
0.01
Market Cap:
$4.27M
Revenue:
-
Net Income/Loss:
$-2.66M
P/E Ratio:
-0.9198
EPS:
-3.0006
Net Cash Flow:
$-2.83M
1W Performance:
+1.10%
1M Performance:
+18.97%
6M Performance:
-5.06%
1Y Performance:
-47.43%
1-Day Range:
$2.7126
$2.785
1-Week Range:
$2.71
$3.06
52-Week Range:
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.76 | 4.29M | 0 | -2.66M | -2.83M | -3.0006 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
XRTX XORTX Therapeutics posts far wider Q1 2024 loss than estimates, shares fall 1.85% amid elevated RD spending.Balance Sheet - Newser
XORTX shareholders approve up-to-5-for-1 share consolidation to meet Nasdaq rules - MSN
XORTX Therapeutics (XRTX) Stock: Pricing Efficiency Review | Q1 2024: Earnings Fall ShortAnalyst Recommended Stocks - Newser
XORTX Therapeutics (NASDAQ: XRTX) registers up to 2.2M shares; $4.7M estimated proceeds - Stock Titan
XORTX Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
XORTX Regains Nasdaq Listing Compliance After Reverse Stock Split - The Globe and Mail
XORTX Therapeutics (NASDAQ: XRTX) files F-1: 2.2M shares, pre-funded warrants - Stock Titan
XRTX SEC FilingsXortx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
XRTX Stock Jumps As VB4-P5 Kidney Deal Expands Pipeline - StocksToTrade
XRTX Stock Jumps As Kidney Pipeline Expands With VB4-P5 Deal - StocksToTrade
XORTX Therapeutics jumps as it confirms Nasdaq bid-price compliance after reverse split - Quiver Quantitative
XORTX (NASDAQ: XRTX) cures Nasdaq minimum bid deficiency - Stock Titan
XRTX Jumps As New Kidney Fibrosis Deal Expands Pipeline - timothysykes.com
XORTX Therapeutics Says Met Nasdaq Continued Listing Requirements - marketscreener.com
XORTX Meets Nasdaq Continued Listing Requirements - GlobeNewswire
Promising Penny Stocks To Add to Your WatchlistApril 21st - MarketBeat
XORTX Therapeutics (XRTX) Stock: Insider Signals (Smart Money Outflows) 2026-04-20Expert Entry Points - Newser
XORTX (NASDAQ: XRTX) closes $3M VB4-P5 kidney anti-fibrotic deal - Stock Titan
Discontinued operations of XORTX Therapeutics, Inc. – DUS:ANU - TradingView — Track All Markets
Long term debt to total equity ratio of XORTX Therapeutics, Inc. – DUS:ANU - TradingView
EBITDA per share of XORTX Therapeutics, Inc. – DUS:ANU - TradingView
Xortx announces closing of acquisition of Vectus kidney anti-fibrotic asset - marketscreener.com
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset - The Manila Times
Hedge Fund Moves: What is the target price for XORTX Therapeutics Inc stockProduct Launch & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
XORTX bets $3M on kidney disease drug candidate VB4-P5 - Stock Titan
Is XORTX Therapeutics Inc vulnerable to short sellers2026 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
XORTX Therapeutics : Investor Presentation - marketscreener.com
Aug Update: Can XORTX Therapeutics Inc continue delivering strong returnsWeekly Trade Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Bond Watch: Is XORTX Therapeutics Inc a speculative investmentWall Street Watch & Low Risk Entry Point Tips - baoquankhu1.vn
Long term debt to total equity ratio of XORTX Therapeutics, Inc. – TRADEGATE:ANU - TradingView — Track All Markets
XORTX Therapeutics Inc. R (ANUA.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
XORTX Therapeutics, Inc. Revenue Breakdown – LS:A427MJ - TradingView
Gross margin % of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
Tangible book value per share of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView
XORTX Therapeutics, Inc. Balance Sheet – LS:A427MJ - TradingView — Track All Markets
Operating cash flow per share of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
XORTX Therapeutics, Inc. Dividends – LS:A427MJ - TradingView — Track All Markets
Discontinued operations of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
Operating margin % of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
Discontinued operations of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView — Track All Markets
EBITDA margin % of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView — Track All Markets
Gross profit of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView — Track All Markets
Cash from investing activities of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
Long term debt to total equity ratio of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView — Track All Markets
Preferred dividends of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView — Track All Markets
XORTX Therapeutics, Inc. Cash Flow – LSX:A427MJ - TradingView — Track All Markets
XORTX Therapeutics, Inc. Cash Flow – LS:A427MJ - TradingView — Track All Markets
Net income before discontinued operations of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
Diluted earnings per share (diluted EPS) of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
Long term debt to total assets ratio of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView
Non-operating income (total) of XORTX Therapeutics, Inc. – LS:A427MJ - TradingView — Track All Markets
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):